PMID- 37026756
OWN - NLM
STAT- MEDLINE
DCOM- 20230710
LR  - 20240418
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 82
IP  - 1
DP  - 2023 Jul 1
TI  - Efficacy and Safety of Different Dosing Regimens of Colchicine in Patients With 
      Coronary Artery Disease: A Network Meta-analysis of 15 Randomized Controlled 
      Trials.
PG  - 13-22
LID - 10.1097/FJC.0000000000001426 [doi]
AB  - Several meta-analyses have investigated the effects of different doses of 
      colchicine in treating coronary artery disease, but all dosing regimens were 
      never compared in a single study. We aimed to compare the efficacy and safety of 
      3 dosing regimens of colchicine in patients with coronary artery disease. PubMed, 
      EMBASE, the Cochrane Library, and SCOPUS were searched for randomized controlled 
      trials involving different colchicine doses. Major adverse cardiac events (MACE), 
      all-cause and cardiovascular mortality, recurrent myocardial infarction (MI), 
      stroke, gastrointestinal adverse events (AEs), discontinuation, and 
      hospitalization were evaluated using risk ratio (RR) with 95% confidence interval 
      (CI). A total of 15 randomized controlled trial involving 13,539 patients were 
      included. Pooled results calculated with STATA 14.0 showed that low-dose 
      colchicine significantly reduced MACE (RR, 0.51; 95% CI, 0.32-0.83), recurrent MI 
      (RR, 0.56; 95% CI, 0.35-0.89), stroke (RR, 0.48; 95% CI, 0.23-1.00), and 
      hospitalization (RR, 0.44; 95% CI, 0.22-0.85), whereas high and loading doses 
      significantly increased gastrointestinal AEs (RR, 2.84; 95% CI, 1.26-6.24) and 
      discontinuation (RR, 2.73; 95% CI, 1.07-6.93), respectively. Sensitivity analyses 
      confirmed that 3 dosing regimens did not reduce all-cause and cardiovascular 
      mortality but significantly increased the gastrointestinal AEs, and high dose 
      significantly increased AEs-related discontinuation; loading dose resulted in 
      more discontinuation than low dose. Although differences between 3 dosing 
      regimens of colchicine are not significant, low dose is more effective in 
      reducing MACE, recurrent MI, stroke, and hospitalization than the control, 
      whereas high and loading doses increase gastrointestinal AEs and discontinuation, 
      respectively.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Shixun
AU  - Wang S
AD  - Department of Cardiology, Weifang People's Hospital, Weifang, Shandong, China.
FAU - Mu, Yanguang
AU  - Mu Y
AD  - Department of Cardiology, Weifang People's Hospital, Weifang, Shandong, China.
FAU - Tan, Lei
AU  - Tan L
AD  - daggerOutpatient Department, Weifang People's Hospital, Weifang, Shandong, China; and.
FAU - Hao, Junqiang
AU  - Hao J
AD  - double daggerDepartment of Emergency Medicine, Weifang Brain Hospital, Weifang, Shandong, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230701
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Humans
MH  - Colchicine/adverse effects
MH  - *Coronary Artery Disease/diagnosis/drug therapy
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke/diagnosis
PMC - PMC10317302
COIS- The authors report no conflicts of interest.
EDAT- 2023/04/08 06:00
MHDA- 2023/07/10 06:42
PMCR- 2023/07/03
CRDT- 2023/04/07 09:23
PHST- 2022/12/25 00:00 [received]
PHST- 2023/03/12 00:00 [accepted]
PHST- 2023/07/10 06:42 [medline]
PHST- 2023/04/08 06:00 [pubmed]
PHST- 2023/04/07 09:23 [entrez]
PHST- 2023/07/03 00:00 [pmc-release]
AID - 00005344-202307000-00002 [pii]
AID - JCVP-23-003 [pii]
AID - 10.1097/FJC.0000000000001426 [doi]
PST - epublish
SO  - J Cardiovasc Pharmacol. 2023 Jul 1;82(1):13-22. doi: 
      10.1097/FJC.0000000000001426.